

Rogier W Sanders

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3508551/rogier-w-sanders-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212
papers

15,357
citations

65
h-index

121
g-index

233
ext. papers

19,230
ext. citations

12.1
avg, IF

6.42
L-index

#	Paper	IF	Citations
212	A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.. <i>Cell Reports Medicine</i> , 2022 , 3, 100486	18	0
211	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection.. <i>Cell Reports Medicine</i> , 2022 , 3, 100528	18	1
210	Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022 , 102, 115650	2.0	0
209	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.. <i>Blood Advances</i> , 2022 ,	7.8	1
208	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers.. <i>Npj Vaccines</i> , 2022 , 7, 27	9.5	1
207	Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns.. <i>PLoS Pathogens</i> , 2022 , 18, e1010340	7.6	2
206	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike.. <i>Scientific Reports</i> , 2022 , 12, 3884	4.9	0
205	Computed Tomography and [F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates.. <i>IScience</i> , 2022 , 104101	6.1	1
204	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers.. <i>Npj Vaccines</i> , 2022 , 7, 44	9.5	0
203	Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody.. <i>Cell Reports Medicine</i> , 2022 , 3, 100635	18	0
202	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.. <i>PLoS Medicine</i> , 2022 , 19, e1003991	11.6	11
201	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle (VLP) Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. <i>Journal of Virology</i> , 2021 , JVI0134321	6.6	1
200	The glycan hole area of HIV-1 envelope trimers contributes prominently to the induction of autologous neutralization. <i>Journal of Virology</i> , 2021 , JVI0155221	6.6	2
199	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. <i>Npj Vaccines</i> , 2021 , 6, 146	9.5	0
198	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. <i>ACS Central Science</i> , 2021 , 7, 1863-1873	16.8	2
197	Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. <i>ELife</i> , 2021 , 10,	8.9	10
196	Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. <i>Journal of the International AIDS Society</i> , 2021 , 24 Suppl 7, e25797	5.4	7

195	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. <i>Nature Communications</i> , 2021 , 12, 6097	17.4	15
194	Virus vaccines: proteins prefer prolines. <i>Cell Host and Microbe</i> , 2021 , 29, 327-333	23.4	25
193	Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva 2021 ,		14
192	Site-specific steric control of SARS-CoV-2 spike glycosylation 2021 ,		3
191	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021 , 184, 1188-1200.e19	56.2	68
190	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021 , 34, 108890	10.6	113
189	Pandemic moves and countermoves: vaccines and viral variants. <i>Lancet, The</i> , 2021 , 397, 1326-1327	40	17
188	SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity. <i>Science Advances</i> , 2021 , 7,	14.3	46
187	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike. <i>Cell Reports</i> , 2021 , 35, 108933	10.6	11
186	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021 , 373, 818-823	33.3	148
185	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021 , 29, 806-818.e6	23.4	24
184	SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. <i>Science Immunology</i> , 2021 , 6,	28	185
183	Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity. <i>Nutrients</i> , 2021 , 13,	6.7	18
182	High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	54
181	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination 2021 ,		7
180	Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. <i>Pathogens and Immunity</i> , 2021 , 6, 116-134	4.9	47
179	Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. <i>Biochemistry</i> , 2021 , 60, 2153-2169	3.2	20
178	Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. <i>Vaccines</i> , 2021 , 9,	5.3	2

177	Influenza A Virus Hemagglutinin Trimer, Head and Stem Proteins Identify and Quantify Different Hemagglutinin-Specific B Cell Subsets in Humans. <i>Vaccines</i> , 2021 , 9,	5.3	3
176	Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. <i>Science</i> , 2021 , 371,	33.3	98
175	SARS-CoV-2 recruits a haem metabolite to evade antibody immunity 2021 ,		8
174	Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. <i>Npj Vaccines</i> , 2021 , 6, 24	9.5	8
173	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants 2021 ,		26
172	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models 2021 ,		10
171	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection 2021 ,		3
170	Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2021 , 6, 103	9.5	1
169	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2021 , 17, e1009736	7.6	3
168	Intramolecular quality control: HIV-1 envelope gp160 signal-peptide cleavage as a functional folding checkpoint. <i>Cell Reports</i> , 2021 , 36, 109646	10.6	1
167	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. <i>Nature Communications</i> , 2021 , 12, 4817	17.4	8
166	Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface. <i>Journal of Virology</i> , 2021 , 95, e0053221	6.6	
165	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021 , 7, eabj5365	14.3	26
164	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. <i>Science</i> , 2021 , 374, 472-478	33.3	72
163	Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. <i>EMBO Journal</i> , 2021 , 40, e106765	13	4
162	Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. <i>EBioMedicine</i> , 2021 , 72, 103589	8.8	3
161	Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice. <i>MAbs</i> , 2020 , 12, 1845908	6.6	1
160	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020 , 369, 643-650	33.3	724

159	HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. <i>Science Advances</i> , 2020 , 6, eaba0512	14.3	10
158	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. <i>Cell</i> , 2020 , 180, 471-489.e22	5.6	47
157	Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions. <i>Structure</i> , 2020 , 28, 897-909.e6	5.2	24
156	Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits. <i>Journal of Virology</i> , 2020 , 94,	6.6	24
155	Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?. <i>Cell Host and Microbe</i> , 2020 , 27, 507-518	23.4	27
154	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. <i>Journal of Virology</i> , 2020 , 94,	6.6	18
153	Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. <i>ELife</i> , 2020 , 9,	8.9	51
152	An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain 2020 ,		8
151	Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity 2020 ,		13
150	Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers. <i>Journal of Virology</i> , 2020 , 94,	6.6	7
149	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. <i>Cell Reports</i> , 2020 , 33, 108274	10.6	107
148	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. <i>Immunity</i> , 2020 , 53, 1272-1280.e5	32.3	112
147	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. <i>PLoS Pathogens</i> , 2020 , 16, e1008665	7.6	25
146	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2020 , 16, e1008753	7.6	37
145	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020 , 16, e1008817	7.6	72
144	Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. <i>Vaccines</i> , 2020 , 8,	5.3	4
143	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens 2020 , 16, e1008665		
142	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens 2020 , 16, e1008665		

141	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens 2020 , 16, e1008665		
140	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens 2020 , 16, e1008665		
139	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates 2020 , 16, e1008753		
138	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates 2020 , 16, e1008753		
137	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates 2020 , 16, e1008753		
136	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates 2020 , 16, e1008753		
135	Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle. <i>Nature Communications</i> , 2019 , 10, 4272	17.4	80
134	HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry. <i>Journal of Biological Chemistry</i> , 2019 , 294, 5736-5746	5.4	11
133	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. <i>Nature Communications</i> , 2019 , 10, 2355	17.4	68
132	Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2019 , 25, 873-883.e5	23.4	25
131	Broadly neutralising antibodies in post-treatment control. <i>Lancet HIV,the</i> , 2019 , 6, e271-e272	7.8	2
130	Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. <i>Viruses</i> , 2019 , 11,	6.2	3
129	Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens. <i>Journal of Pharmaceutical Sciences</i> , 2019 , 108, 2264-2277	3.9	11
128	Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. <i>Journal of Biological Chemistry</i> , 2019 , 294, 5616-5631	5.4	14
127	Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide. <i>Nature Communications</i> , 2019 , 10, 763	17.4	13
126	Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. <i>Journal of Virology</i> , 2019 , 93,	6.6	9
125	Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics. <i>PLoS Pathogens</i> , 2019 , 15, e1007920	7.6	41
124	Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms. <i>Current Opinion in HIV and AIDS</i> , 2019 , 14, 302-308	4.2	17

123	The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1. <i>Frontiers in Immunology</i> , 2019 , 10, 2793	8.4	
122	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019 , 50, 241-252.e6	32.3	96
121	Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. <i>Journal of Virology</i> , 2019 , 93,	6.6	50
120	Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. <i>Journal of Proteome Research</i> , 2018 , 17, 987-999	5.6	18
119	Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. <i>Journal of Virology</i> , 2018 , 92,	6.6	50
118	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. <i>PLoS Pathogens</i> , 2018 , 14, e1006986	7.6	22
117	Variable Domain -Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability. <i>Frontiers in Immunology</i> , 2018 , 9, 740	8.4	19
116	Short Communication: Protective Efficacy of Broadly Neutralizing Antibody PGDM1400 Against HIV-1 Challenge in Humanized Mice. <i>AIDS Research and Human Retroviruses</i> , 2018 , 34, 790-793	1.6	6
115	Hitting HIV's Harpoon. <i>Immunity</i> , 2018 , 49, 14-15	32.3	4
114	Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen. <i>Cell Reports</i> , 2018 , 24, 1958-1966.e5	10.6	89
113	Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. <i>PLoS Pathogens</i> , 2018 , 14, e1006913	7.6	78
112	Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. <i>Journal of Biological Chemistry</i> , 2018 , 293, 1688-1701	5.4	26
111	cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. <i>Biotechnology and Bioengineering</i> , 2018 , 115, 885-899	4.9	56
110	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018 , 49, 1162-1174.e8	32.3	32
109	Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. <i>Retrovirology</i> , 2018 , 15, 63	3.6	25
108	Harnessing post-translational modifications for next-generation HIV immunogens. <i>Biochemical Society Transactions</i> , 2018 , 46, 691-698	5.1	2
107	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	96
106	Native-like Env trimers as a platform for HIV-1 vaccine design. <i>Immunological Reviews</i> , 2017 , 275, 161-182	21.3	166

105	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017 , 18, 2175-2188	10.6	50
104	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017 , 46, 1073-1088.e6	32.3	204
103	Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. <i>Journal of Virology</i> , 2017 , 91,	6.6	33
102	Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. <i>Journal of Virology</i> , 2017 , 91,	6.6	19
101	Three mutations switch H7N9 influenza to human-type receptor specificity. <i>PLoS Pathogens</i> , 2017 , 13, e1006390	7.6	65
100	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. <i>Cell Reports</i> , 2017 , 20, 1805-1817	10.6	112
99	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. <i>Journal of Experimental Medicine</i> , 2017 , 214, 2573-2590	16.6	100
98	High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers. <i>Journal of Virology</i> , 2017 , 91,	6.6	17
97	The microanatomic segregation of selection by apoptosis in the germinal center. <i>Science</i> , 2017 , 358,	33.3	114
96	Opposites attract in bispecific antibody engineering. <i>Journal of Biological Chemistry</i> , 2017 , 292, 14718-14719	1.9	2
95	A single mutation in Taiwanese H6N1 influenza hemagglutinin switches binding to human-type receptors. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1314-1325	12	30
94	HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. <i>PLoS ONE</i> , 2017 , 12, e0181886	3.7	13
93	Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide. <i>ELife</i> , 2017 , 6,	8.9	26
92	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. <i>Cell Reports</i> , 2016 , 16, 2327-38	10.6	163
91	Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. <i>Cell Reports</i> , 2016 , 17, 2195-2209	10.6	110
90	HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds. <i>Retrovirology</i> , 2016 , 13, 48	3.6	17
89	Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens. <i>Journal of Virology</i> , 2016 , 90, 813-28	6.6	30
88	Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. <i>Journal of Immunology</i> , 2016 , 197, 994-1002	5.3	89

87	HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. <i>Expert Review of Vaccines</i> , 2016 , 15, 349-65	5.2	38
86	HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. <i>Trends in Immunology</i> , 2016 , 37, 221-232	14.4	78
85	Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. <i>Cell Reports</i> , 2016 , 14, 2695-706	10.6	193
84	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. <i>Nature Microbiology</i> , 2016 , 2, 16199	26.6	103
83	Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. <i>PLoS Pathogens</i> , 2016 , 12, e1005864	7.6	101
82	The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 1135-1142	1.6	10
81	D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 52	3.1	5
80	Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E6639-E6648	11.5	164
79	HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. <i>Science</i> , 2015 , 349, aac4223	33.3	394
78	Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 1160-5	1.6	10
77	What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?. <i>Journal of Virology</i> , 2015 , 89, 5981-95	6.6	19
76	Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. <i>PLoS Pathogens</i> , 2015 , 11, e1004767	7.6	85
75	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. <i>Cell</i> , 2015 , 161, 1505-1512	16.2	197
74	A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. <i>Journal of Virology</i> , 2015 , 89, 3380-3395	6.95	191
73	Immunosilencing a highly immunogenic protein trimerization domain. <i>Journal of Biological Chemistry</i> , 2015 , 290, 7436-42	5.4	40
72	Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2015 , 71, 2099-108		54
71	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. <i>Nature Communications</i> , 2015 , 6, 8167	17.4	62
70	Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. <i>Journal of Virology</i> , 2015 , 89, 10383-98	6.6	105

69	Reactivation of Neutralized HIV-1 by Dendritic Cells Is Dependent on the Epitope Bound by the Antibody. <i>Journal of Immunology</i> , 2015 , 195, 3759-68	5.3	3
68	Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 11947-52	11.5	97
67	Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. <i>Journal of Virology</i> , 2015 , 89, 12189-210	6.6	66
66	Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers. <i>Virology</i> , 2015 , 486, 116-20	3.6	32
65	Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. <i>Retrovirology</i> , 2015 , 12, 82	3.6	111
64	Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer. <i>Biomolecules</i> , 2015 , 5, 2919-34	5.9	9
63	Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals. <i>PLoS ONE</i> , 2015 , 10, e0120648	3.7	4
62	Colorectal mucus binds DC-SIGN and inhibits HIV-1 trans-infection of CD4+ T-lymphocytes. <i>PLoS ONE</i> , 2015 , 10, e0122020	3.7	10
61	Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. <i>PLoS Pathogens</i> , 2015 , 11, e1005110	7.6	61
60	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. <i>PLoS Pathogens</i> , 2015 , 11, e1005238	7.6	36
59	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. <i>Cell</i> , 2015 , 163, 1702-15	56.2	251
58	Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. <i>Immunity</i> , 2015 , 43, 1053-63	32.3	170
57	Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. <i>Cell Reports</i> , 2015 , 11, 1604-13	10.6	101
56	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. <i>Nature Communications</i> , 2015 , 6, 6144	17.4	101
55	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014 , 509, 55-62	50.4	537
54	Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. <i>Immunity</i> , 2014 , 40, 669-80	32.3	267
53	ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2014 , 1838, 1296-305	3.8	22
52	Bypass of Quality Control in Protein Folding Pathways Induces Specific Misfolding of HIV Envelope V2 Loop: Implications for Iminosugars as Antivirals. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A49-A49	1.6	

51	HIV: A stamp on the envelope. <i>Nature</i> , 2014 , 514, 437-8	50.4	24
50	Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. <i>Retrovirology</i> , 2014 , 11, 41	3.6	121
49	Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. <i>Nature</i> , 2014 , 515, 138-42	50.4	330
48	In vivo protection by broadly neutralizing HIV antibodies. <i>Trends in Microbiology</i> , 2014 , 22, 550-1	12.4	41
47	CD4-induced activation in a soluble HIV-1 Env trimer. <i>Structure</i> , 2014 , 22, 974-84	5.2	101
46	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 17624-9	11.5	239
45	A Recombinant HIV Envelope Trimer Selects for Quaternary Dependent Antibodies Targeting the Trimer Apex. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A7-A8	1.6	3
44	Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. <i>Aids</i> , 2014 , 28, 1237-40	3.5	18
43	Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. <i>Immunity</i> , 2014 , 40, 657-68	32.3	286
42	Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL. <i>PLoS ONE</i> , 2014 , 9, e107683	3.7	3
41	Crystal structure of a soluble cleaved HIV-1 envelope trimer. <i>Science</i> , 2013 , 342, 1477-83	33.3	687
40	Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. <i>Science</i> , 2013 , 342, 1484-90	33.9	573
39	HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. <i>Retrovirology</i> , 2013 , 10, 102	3.6	37
38	Broadly neutralizing antibodies against HIV-1: templates for a vaccine. <i>Virology</i> , 2013 , 435, 46-56	3.6	88
37	HIV takes double hit before entry. <i>BMC Biology</i> , 2013 , 10, 99	7.3	2
36	Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. <i>Nature Structural and Molecular Biology</i> , 2013 , 20, 796-803	17.6	274
35	Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. <i>PLoS Pathogens</i> , 2013 , 9, e1003342	7.6	235
34	A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. <i>PLoS Pathogens</i> , 2013 , 9, e1003618	7.6	644

33	Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 4351-6	11.5	214
32	How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1-15	1.6	67
31	A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. <i>Science</i> , 2011 , 334, 1097-103	33.3	576
30	Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. <i>Virology</i> , 2010 , 401, 236-47	3.6	64
29	Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. <i>Journal of Biological Chemistry</i> , 2009 , 284, 26941-50	5.4	64
28	Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. <i>Journal of Virology</i> , 2009 , 83, 368-83	6.6	37
27	Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. <i>Virology</i> , 2009 , 389, 108-21	3.6	44
26	The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. <i>Retrovirology</i> , 2008 , 5, 10	3.6	40
25	Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. <i>Molecular Biology of the Cell</i> , 2008 , 19, 4298-309	3.5	38
24	Evolution rescues folding of human immunodeficiency virus-1 envelope glycoprotein GP120 lacking a conserved disulfide bond. <i>Molecular Biology of the Cell</i> , 2008 , 19, 4707-16	3.5	10
23	HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. <i>PLoS Pathogens</i> , 2007 , 3, e169	7.6	124
22	Protein promiscuity: drug resistance and native functions--HIV-1 case. <i>Journal of Biomolecular Structure and Dynamics</i> , 2005 , 22, 615-24	3.6	19
21	Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 742-9	1.6	20
20	Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. <i>Retrovirology</i> , 2004 , 1, 3	3.6	30
19	Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. <i>Journal of Virology</i> , 2002 , 76, 8875-89	6.6	366
18	The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. <i>Journal of Virology</i> , 2002 , 76, 7293-305	6.6	507
17	Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. <i>Journal of Virology</i> , 2002 , 76, 7760-76	6.6	146
16	Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. <i>Journal of Virology</i> , 2002 , 76, 2606-16	6.6	120

15	Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. <i>Journal of Virology</i> , 2002 , 76, 7812-21	6.6	126
14	A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. <i>Journal of Virology</i> , 2000 , 74, 627-43	6.6	453
13	Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits. <i>Journal of Virology</i> , 2000 , 74, 5091-5100	6.6	4
12	Mapping the antigenic diversification of SARS-CoV-2		12
11	Networks of HIV-1 envelope glycans maintain antibody epitopes in the face of glycan additions and deletions	2	
10	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates		7
9	Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike		6
8	Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses		30
7	Infection and transmission of SARS-CoV-2 depends on heparan sulfate proteoglycans		5
6	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection		1
5	Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patients		4
4	Probing Affinity, Avidity, Anti-Cooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses		1
3	Cross-reactive antibodies after SARS-CoV-2 infection and vaccination		3
2	Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants		14
1	Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM		1